cancer of unknown primary
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.
Gene Expression Assay Shows Ability to Guide Targeted Treatment for Patients With Occult Cancers
Premium
Patients with cancers of unknown primary had more treatment options and better outcomes when care was informed by a 90-gene expression assay.
Real-World Study Examines Genomic Profiling Challenges for Patients With Cancers of Unknown Primary
Premium
The researchers found that more than half of patients with CUP did not have sufficient tissue to undergo genomic profiling.